Foresite Capital Management VI LLC bought $3.1M of Alumis (ALMS)
Executed Nov 17 2025, disclosed Nov 20 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Nov 19 2025), the stock returned +73.6% (delay-adjusted); from the execution session (Nov 17 2025), +106.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Foresite Capital Management VI LLC (10% owner) filed 3 Form 4 reports as a reporting entity in the trailing twelve months (3 purchases, 0 sales), most often in Alumis Inc. (ALMS). Across 3 priced purchase filings, the average 21-session return was +71.1% from execution and +54.8% from disclosure (delay-adjusted; derived). The largest single filing was $7.0M of ALMS (411,764 sh across 2 lots, as filed), executed Jan 8.
Healthcare · Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disor…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→411,764 sh across 2 lots
Exec Jan 8
Filed Jan 12 · 9:58 PM ET ALMSPURCHASE Alumis Inc. $533K
72,212 sh × $7.38
Exec Nov 21 2025
Filed Nov 25 2025 · 4:02 PM ET